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Abstract: Pulmonary arterial hypertension (PAH) is a rare fatal disease defined as a sustained elevation of pulmonary ar-
terial pressure to more than 25 mmHg at rest, with a mean pulmonary-capillary wedge pressure and left ventricular end-
diastolic pressure of less than 15 mmHg at rest. Histopathology of PAH is founded on structural modifications on the vas-
cular wall of small pulmonary arteries characterized by thickening of all its layers. These changes, named as vascular re-
modelling, include vascular proliferation, fibrosis, and vessel obstruction. In clinical practice the diagnosis of PAH relies 
on measurements of pulmonary vascular pressure and cardiac output, and calculation of pulmonary vascular resistances. 
Direct evaluation of pulmonary vascular structure is not routinely performed in pulmonary hypertension since current im-
aging techniques are limited and since little is known about the relationship between structural changes and functional 
characteristics of the pulmonary vasculature. Intravascular ultrasound studies in patients with pulmonary hypertension 
have shown a thicker middle layer, increased wall-thickness ratio and diminished pulsatility than in control patients. Opti-
cal Coherence Tomography, a new high resolution imaging modality that has proven its superiority over intravascular ul-
trasound (IVUS) for the detection and characterization of coronary atherosclerotic plaque composition, may potentially be 
a useful technique for the in vivo study of the pulmonary arterial wall. In addition current progress in Echo Doppler tech-
nique will quantify right ventricular function with parameters independent of loading conditions and not requiring volu-
metric approximations of the complex geometry of the right ventricle. This would allow the in vivo study of right ven-
tricular and pulmonary artery remodelling in PAH. 
INTRODUCTION 
  Pulmonary arterial hypertension (PAH) is a rare fatal 
disease defined as a sustained elevation of pulmonary arterial 
pressure to more than 25 mmHg at rest, with a mean pulmo-
nary-capillary wedge pressure and left ventricular end-
diastolic pressure of less than 15 mmHg at rest. Its fatal 
evolution brings patients to death, due to right ventricular 
failure in an average time of three years [1]. PAH incidence 
is estimated in 2.4-8 patients per million/year and its preva-
lence is 15-30 patients per million [2, 3]. 
  The majority of PAH are idiopathic, while the rest may 
be: familial, associated with collagen diseases, congenital 
systemic-to-pulmonary shunts, portal hypertension, HIV 
infection, drugs and toxins [anorexigens, fenfluramine, rape-
seed oil] and persistent pulmonary hypertension of the new-
born [4]. 
  PAH is a disease with a complex and not completely 
understood pathophysiology. Several pathophysiological 
pathways seem to be involved: prostaglandin pathway,   
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acting on AMPc generation that can be fostered by the ad-
ministration of prostacycline analogues [epoprostenol, 
treprostinil, iloprost, beraprost]; nitric oxide pathway, en-
hancing the production of GMPc, which is inhibited by 
phosphodiesterase-V that can be blocked by its inhibitors 
[sidenafil, tadalafil]; and the endothelin-1 pathway, acting as 
a potent endothelial vasoconstrictor that can be partially 
blocked by endothelin receptor antagonists [bosentan, am-
brisentan, sitaxentan] [5]. New physiophatologic pathways 
including angiogenesis, TGF-, serotonin, and cellular pro-
liferation mechanisms are coming out and appear to be rele-
vant in vascular structural changes related to PAH [6]. 
HISTOPATHOLOGY AND VASCULAR REMODEL-
LING 
  Histopathology of PAH is founded on structural modifi-
cations on the vascular wall of small pulmonary arteries 
characterized by thickening of all its layers. These changes 
named as vascular remodelling include vascular prolifera-
tion, fibrosis, and vessel obstruction. Development of PAH 
involves the complex interaction of multiple vascular effec-
tors at all anatomic levels of the arteriolar wall. Subsequent 
vasoconstriction, thrombosis, and inflammation ensue, lead-
ing to vessel wall remodelling and cellular hyperproliferation 
as hallmarks of disease severity. These processes are influ-32    The Open Respiratory Medicine Journal, 2009, Volume 3  Domingo et al. 
enced by genetic predisposition as well as endogenous and 
exogenous stimuli. The final result of this process is that 
arterial vascular wall becomes thicker and more rigid modi-
fying its behaviour in terms of elasticity, pulsatility and 
compliance. 
  Nowadays triggers of pulmonary vascular remodelling 
remain unknown. However it has been suggested that some 
mesenquimal undifferentiated cells placed on the vascular 
divisions where muscular smooth cell layer begins to disap-
pear, may differentiate into smooth muscle cells due to ex-
ogenous stimuli, not recognized yet. A second hypothesis 
that would explain why myofibroblasts are the predominant 
cells in the hypertrophied muscular layer in PAH suggest 
that interstitial and adventitial fibroblasts, once activated, 
can differentiate into myofibroblasts that would migrate to 
the muscular layer. It has also been proposed that bone mar-
row stem cells could play a role in this process. When lung 
suffers an aggression or an inflammation mediated by cyto-
kines, there is a release of bone marrow progenitor cells with 
the capability of differentiate in endothelial cells that would 
repair the damaged zone. There is some research in mice 
which demonstrates the migration of stem cells to the vessel 
wall if the animal is under hypoxia, showing that these cells 
could then proliferate and differentiate into smooth muscle 
cells [7-11]. Finally, there is the endothelial-to-mesenchymal 
transition theory, imported from the pathogeny of cancer and 
based on the endothelium ability of change into a mesen-
quimal tissue composed by smooth muscle cells after its 
stimulation by aggressions and growth and transforming 
factors [12]. A common phenomenon already demonstrated 
whatever the ethiology of the disease is, is that affected ves-
sels show a lesser number of smooth muscle and intimal 
apoptotic cells, deed that favours indirectly the process of 
hyperplasia and hypertrophy of these cells [13]. 
Intimal Lesions 
  Intimal lesions largely influence the overall pulmonary 
vascular resistance. There are three kinds of lesions respon-
sible of intimal remodelling, which appear sequentially along 
disease progression. The initial lesion consists on abnormal 
vasculogenesis leading to plexiform and angiomatoid le-
sions, typically located on vascular division points. This 
event shares characteristics and etiologic factors with some 
neoplasia, since absence of antiremodelating mediators and 
tumoral suppressor factors have been observed [13-15]. 
Plexiform lesions progress into “onion skin” lesions devel-
oped from intimal myofibroblasts and endothelial cells, both 
growing uncontrolled in concentric layers reducing signifi-
cantly the luminal area [16]. The final stage of this process 
consists on accumulation of scarring extracellular matrix that 
contributes to occlusion phenomenon. 
Medial Lesions 
  Medial thickening plays an important role in PAH patho-
genesis, though a relationship between the degree of remod-
elling and the severity of the disease or the response to 
treatment has not been clearly demonstrated yet. Two factors 
have been suggested as triggers for medial remodelling: 
mutations in bone morphogenetic protein receptor 2 
[BMPR2], implicated in the genesis of the disease [17] and 
vascular smooth muscle cells in PAH expressing higher 
levels of serotonin that promotes vasoconstriction, cell 
growth and enhances hypoxia induced remodelling [18]. 
Medial changes involve muscularized arteries and precapil-
lary vessels where medial layer thickening is due to a com-
bination of smooth muscle cells hypertrophy, and hyperpla-
sia with a deposition of extracellular matrix and thickening 
of elastic laminae [19]. 
Adventitial Lesions 
  Adventitial thickening is mostly due to collagen deposi-
tion but fibroblasts also contribute with its sensitive response 
to stimulus like hypoxia or increased vascular pressure. This 
induces, due to their biological heterogeneity, differentiation 
into smooth muscle cells that migrate to medial layer, stimu-
lation medial smooth muscle cells proliferation by secretion 
of growth factors, allowing the recruitment of inflammatory 
and bone marrow progenitors cells and creating a vasculo-
genic niche for the expansion of newly formed vessels [20]. 
All these changes promote development of PAH. 
  As already previously pointed in the introduction, death 
in PAH is usually due to terminal right cardiac failure. 
  Right ventricle is the main victim of the hemodynamic 
consequences of PAH. The adaptative fight against chroni-
cally elevated pulmonary vascular resistances resistances 
induces structural changes in the right ventricle that progres-
sively leads to its functional impairment. Because of this, a 
renew interest in studying right ventricle in PAH has arisen 
nowadays. Doppler echocardiographic technology appears to 
be the most useful technique for the non invasive evaluation 
of right ventricular function in the clinical setting. 
  Hitherto, our knowledge about vascular remodelling 
mainly comes from autopsy studies as lung tissue is not 
usually available during the course of the disease. This fact 
has hindered all the investigations in this field but lastly, new 
vascular exploratory technologies like intravascular ultra-
sound (IVUS) or optical coherence tomography have arisen 
as potentially practical tools for the in vivo study of vascular 
changes in PAH. 
  Along this article we will go into exploratory techniques 
for evaluating vascular and cardiac remodelling in PAH 
focusing on new invasive techniques and advances in echo-
cardiography. 
INVASIVE AND NON INVASIVE EVALUATION OF 
PULMONARY ARTERIAL WALL AND RIGHT VEN-
TRICLE 
  In clinical practice the diagnosis of Pulmonary Hyperten-
sion relies on measurements of pulmonary vascular pressure 
and cardiac output, and calculation of pulmonary vascular 
resistances [21]. These hemodynamic measurements are of 
prognostic value, with survival being related to cardiac out-
put rather than to pulmonary pressure. Clinical signs of right 
ventricular failure often are not clearly related to progression 
of pulmonary hypertension as assessed by pulmonary pres-
sure and resistance. This observation may be explained by 
the fact that heart failure in pulmonary hypertension is the 
consequence of both global changes of right ventricular 
overload, not only in pulmonary vascular resistances, and the 
consequence of uncoupling of right ventricle to the hyperten-
sive pulmonary circulation, which is not actually measured 
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Pulmonary Arterial Wall 
  Direct evaluation of pulmonary vascular structure is not 
routinely performed in pulmonary hypertension since current 
imaging techniques are limited and since little is known 
about the relationship between structural changes and func-
tional characteristics of the pulmonary vasculature. Intravas-
cular ultrasound studies in patients with pulmonary hyper-
tension have shown a thicker middle layer, increased wall-
thickness ratio (Fig. 1) and diminished pulsatility than in 
control patients [23,24]. However vasoreactivity to nitric 
oxyde, oxygen or epoprostenol does not appear to correlate 
with structural assessment of pulmonary vascular wall by 
intravascular ultrasound (IVUS) [23, 24]. IVUS provides 
combined morphological and functional evaluation of the 
elastic pulmonary vessels of patients with pulmonary hyper-
tension and allows direct assessment of the acute changes 
induced in the pulmonary vessel wall dynamics by epopros-
tenol. The exploration is safe, and can be undertaken at the 
same time of cardiac catheterization. In addition there is an 
association between impaired pulmonary artery functional 
state as determined by IVUS and mortality at follow-up. 
However larger series are needed to determine the exact 
prognostic value of this technique in the setting of pulmo-
nary hypertension [23]. 
 
Fig. (1). Image of IVUS of a pulmonary artery in a patient with 
Pulmonary Arterial Hypertension. Calculation of amount of fibrosis 
of the arterial wall. 
  It has to be taken into account that pulmonary arteries, in 
contrast to systemic arteries, have a much thinner smooth 
muscle layer under normal conditions, consistent with a low 
pressure system, and that, as an approximation, the pulmo-
nary vascular resistance is divided equally between arteries, 
capillaries and veins [25]. In addition the pulmonary circula-
tion is a low pressure, low resistance, highly distensible 
system. Recently it has been shown that total compliance of 
the pulmonary vascular bed, defined as the ratio of stroke 
volume to pulse pressure, predicts mortality in patients with 
pulmonary arterial hypertension [26]. A large part of total 
vascular bed compliance is located in the proximal arterial 
branches. Therefore the predictive value of pulmonary vas-
cular compliance in chronic pulmonary arterial hypertension 
also pertains to increased stiffness of the proximal pulmo-
nary arteries. 
  Pulmonary arterial hypertension is basically a disease of 
small distal pulmonary arteries, leading to an increase in 
pulmonary vascular resistances, and as a result, pulmonary 
arterial pressure. Increased pressure causes distension and 
stiffening of the proximal pulmonary artery, causing vessel 
wall remodelling, which in itself may influence stiffness. 
  As already known pulmonary arterial hypertension can 
have a variety of different causes, but all causes have an 
increased right ventricular afterload in common. Because 
this increased afterload may lead to ventricular hypertrophy, 
right ventricular failure and ultimately death, it is important 
to insure our understanding of the right ventricular afterload. 
Most often in the clinical setting this afterload is defined as 
pulmonary vascular resistance. Because pulmonary vascular 
resistance is the ratio of mean pressure and mean flow, it 
reflects the arterial load to a steady flow. However blood 
flow is pulsatile, and thus a complete description of ventricu-
lar afterload should also include the load to a pulsatile flow. 
A decreased arterial compliance, for example, may be of 
similar importance for ventricular afterload as an increased 
pulmonary vascular resistance [27]. 
  Another determinant of right ventricular afterload that is 
neither reflected by resistance or compliance is the charac-
teristic impedance of the proximal pulmonary arteries, which 
combines both blood inertia and vascular storage properties. 
A model that combines the 3 components of ventricular 
afterload is the 3 element windkessel model [28]. However 
there is not much information of the application of this 
model in the analysis of the pulmonary circulation. 
  These considerations on the different elements of the 
circulation contributing to right ventricular afterload may 
explain why pulmonary vascular resistance is a poor predic-
tor of clinical prognosis in pulmonary arterial hypertension 
[22]. In addition in the pulmonary circulation the pulsatile 
components of pressure and flow contribute much as one 
third to one half of the total hydraulic power that is trans-
ferred from the right ventricle to the pulmonary vascular bed. 
As a consequence pulsatility plays a more important role in 
the pulmonary than in the systemic circulation. Pulsatility 
and mismatching of the right ventricle to its afterload may 
therefore better explain signs of clinical worsening than 
variables related to steady flow such as pressure and resis-
tance [22, 23]. Therefore since pulmonary arterial compli-
ance measures how much the aggregate pulmonary arterial 
tree will dilate with each contraction of the right ventricle, it 
should be inversely proportional to the workload on the right 
heart, and thus compliance will be more important than resis-
tance in the long run right ventricular remodelling, and con-
sequently a better predictor of prognosis and mortality in 
pulmonary arterial hypertension [23]. 
  As already mentioned IVUS has been validated as a reli-
able method for describing pulmonary vessel wall morphol-
ogy [23-30]. Recently Optical Coherence Tomography 
(OCT) a new high resolution imaging modality has proven 
its superiority over IVUS for the detection and characteriza-
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tion of coronary atherosclerotic plaque composition, specifi-
cally for the differentiation of non-calcified, lipid rich, or 
fibrous plaque [31]. However, at the moment no literature 
exists on the use of OCT in primary pulmonary hyperten-
sion. Optical Coherence Tomography is based on the meas-
urement of the back-reflection of infra-red light. The princi-
ple of OCT has been described by other groups [32, 33]. 
  The most important advantage of OCT over other intra-
vascular imaging modalities is its superior resolution, that 
will probably allow a more precise quantification of the 
arterial wall fibrosis. 
Right Ventricle 
  Clinical signs of right ventricular failure vary greatly in 
the presence of similar severity of pulmonary arterial pres-
sure. Pulmonary arterial pressure and pulmonary vascular 
resistance are not sufficient to evaluate right ventricular 
afterload because this composite variable is flow dependent 
and because it does not integrate changes in arterial elastance 
and wave reflection. As the clinical consequences of pulmo-
nary hypertension relate to the ability of right ventricular 
function to maintain adapted flow output, quantifying ven-
tricular-arterial coupling appears to be a more logical hemo-
dynamic approach [34]. Although this approach basically 
requires measurements of instantaneous right ventricular 
volumes, bedside application will obviously require a more 
simplified and non invasive approach. Current progress in 
Echo Doppler technology will probably make this possible 
allowing for point by point calculation of right ventricular 
pressure curves from the envelop of tricuspid regurgitant jets 
and synchronized measurement of instantaneous pulmonary 
arterial flow [35,36]. 
  Methods for assessing right ventricular function include 
echocardiography, MRI, intermittent hemodynamic monitor-
ing, implantable hemodynamic monitors, nuclear medicine, 
natriuretic peptide levels as well as indirect measures such as 
cardiopulmonary exercise testing. In the clinical setting 
echocardiography is clearly the most used and reliable tech-
nique. 
  The presence of pericardial effusion has long been rec-
ognized as an end-stage prognostic finding, occurring when 
the right heart fails. The degree of septal shift in diastole, 
and its correlate the eccentricity index, is also related to 
outcome and to improvement with effective therapy [37] 
(Fig. 2). However, these parameters depict ventricular fail-
ure, but do not directly assess right ventricular function. 
  The majority of the proposed methods of echocardio-
graphic assessment of right ventricular function are based on 
volumetric approximations of the right ventricle. However 
such approaches have intrinsic limitations, first since volume 
related measures such as ejection fraction are load depend-
ent, second because of the complex geometry of the right 
ventricle [38]. The issue of right ventricular geometry is 
usually overcome using the so called geometry independent 
parameters such as tricuspid annular velocity and tricuspid 
annular plane systolic excursion (TAPSE) [39] (Fig. 3) and 
three dimensional echocardiography [40]. Nevertheless as-
sessments based on tricuspid annular excursion have impor-
tant inherent limitations as independent measurements of 
 
Fig. (2). Short axis view of the right [upper] and left ventricle in a patient with PAH. It can be seen important septal shift [arrows] at the 
beginning of diastole that added to the right ventricle enlargement contributes to an important increase in the eccentricity index (quantifying 
the spherical shape of the right ventricle). RV: right ventricle. LV: left ventricle. IVS: interventricular septum. 
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right ventricular pumping function [41]. However, is it really 
necessary to analyse right ventricular volumes in order to 
calculate a variable so dependent on post load such as ejec-
tion fraction, particularly in a clinical setting where afterload 
is so important, such as pulmonary hypertension? It appears 
that the Echo Doppler technology will be more logically 
applied to the study of functional aspects unable to be quan-
tified by other imaging techniques. 
  Another promising tool for right ventricular assessment is 
tissue doppler imaging techniques, but at present, data are 
relatively scarce and variability of results are still too high to 
rely only in this method for right ventricular function analy-
sis in pulmonary hypertension (Fig. 4). However some stud-
ies have already reported normal range of mechanical vari-
ables in Doppler imaging studies [42], have shown evidence 
of interventricular dyssynchrony in pulmonary hypertension 
 
Fig. (3). Tricuspid Annular Plane Systolic Excursion [TAPSE] in a patient with severe PAH during a vasodilatory test with epoprostenol: 
Left panel depicts the localization of the cursor line over the lateral portion of the tricuspid annulus on an apical view of the right heart 
chambers [RV: right ventricle; RA: right atrium]. On the right panel the M-mode represents displacement of the annular plane during the 
cardiac cycle. Main advantages of TAPSE, despite its dependency on volumetric assumptions, are that it is very easy to obtain and quite 
reproducible. 
 
Fig. (4). Tissue Doppler Imaging [TDI] of the Right Ventricle [RV]: Pulsed Wave Doppler as depicted in the image allows the analysis of 
regional velocities and measurement of both peak systolic and isovolumic acceleration [IVA] at different levels of the RV free wall. These 
parameters although not completely independent of loading conditions may offer information about RV systolic function that at least does 
not rely on geometric or volumetric assumptions. 
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[43] and have related these variables to serum levels of brain 
natriuretic peptide [44]. In addition even some variables, 
such as apical strain rate (Fig. 5), have been correlated with 
pulmonary artery pressures [45]. 
CONCLUSIONS 
  We firmly believe that the remodelling process of the 
pulmonary vasculature and the right ventricle play an impor-
tant role in the evolution of PAH and thus must be part of the 
evaluation of the disease progression and of the response to 
pharmacological treatments. Techniques such as IVUS, OCT 
and new Echo Doppler technology will probably allow to 
study in vivo this remodelling process. 
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